To further explore the role of TG2 on motility, we employed the NC9 inhibitor to treat mesenchymal-like MDA-MB-231 cells that were expressing high basal levels of TG2 (as compared to MCF-7 cells), representing a breast tumor model with more advanced malignant features. Here, TGM2 is linked to breast neoplasm.